An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation

Trial Profile

An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2016

At a glance

  • Drugs IX 01 (Primary)
  • Indications Premature ejaculation
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PEPIX
  • Sponsors Ixchelsis
  • Most Recent Events

    • 25 Jan 2016 Primary endpoint (Mean fold change in geometric Mean IELT) has been met, according to an Ixchelsis media release.
    • 25 Jan 2016 Results were published in an Ixchelsis media release.
    • 19 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top